October 20, 2021
RegMed Investors’ (RMi) closing bell: pain follows gains with today’s spin down the drain while volume remains low
October 19, 2021
RegMed Investors’ (RMi) closing bell: the sun shines on the sector and optimism abounds
October 18, 2021
RegMed Investors’ (RMi) closing bell: one word re share pricing - fear
October 15, 2021
RegMed Investors’ (RMi) closing bell: another I foretold you so
October 14, 2021
RegMed Investors’ (RMi) closing bell: hangin’ with the upside although low volume is a problem
October 13, 2021
RegMed Investors’ (RMi) closing bell: a broad-brush approach and sector review
October 12, 2021
RegMed Investors’ (RMi) closing bell: love the upside but, the highs won’t last as Q3 results are being prepared for disposition
October 11, 2021
RegMed Investors’ (RMi) closing bell: sector’s incline accelerates as session progresses
October 8, 2021
RegMed Investors’ (RMi) closing bell: another stem, cell and gene therapy sector struggle as indexes dive
October 7, 2021
RegMed Investors’ (RMi) closing bell: the oversold were ripe to be picked
October 6, 2021
RegMed Investors’ (RMi) closing bell: stem, cell and gene therapy sector stumbles
October 5, 2021
RegMed Investors’ (RMi) closing bell: a barely upside turnaround
October 4, 2021
RegMed Investors’ (RMi) closing bell: sector was under heavy pressure, with a muddy path forward for sector equities
October 1, 2021
RegMed Investors’ (RMi) closing bell: Back from the depths to close positive
September 30, 2021
RegMed Investors’ (RMi) closing bell: sector closes the month with a slip and fall
September 29, 2021
RegMed Investors’ (RMi) closing bell: called it volatile and liquid this a.m., it was
September 28, 2021
RegMed Investors’ (RMi) closing bell: Déjà vu, the deep end
September 27, 2021
RegMed Investors’ (RMi) closing bell: risks are mounting as sentiment seems AWOL
September 24, 2021
RegMed Investors’ (RMi) closing bell: this morning’s “twitch” came to fruition
September 23, 2021
RegMed Investors’ (RMi) closing bell: lucky sector up day with low volume but, risk is still lurking
September 22, 2021
RegMed Investors’ (RMi) closing bell: back in the green after a volatile session
September 21, 2021
RegMed Investors’ (RMi) closing bell: a buying opportunity for the stem cell and gene therapy sector
September 17, 2021
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector rebounds from the quadruple witching swallowing fear
September 16, 2021
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector share pricing beat-back quadruple witching
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.